Thesis

18 Chapter 1 15. Leuzy A, Chiotis K, Lemoine L, Gillberg P-G, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies—still a challenge. Molecular psychiatry. 2019;24:1112-34. 16. Barthel H. First tau PET tracer approved: toward accurate in vivo diagnosis of Alzheimer disease. Soc Nuclear Med; 2020. p. 1409-10. 17. Lammertsma AA. Forward to the past: the case for quantitative PET imaging. Journal of Nuclear Medicine. 2017;58:1019-24. 18. Ossenkoppele R, Prins ND, Van Berckel BN. Amyloid imaging in clinical trials. Alzheimer’s research & therapy. 2013;5:1-3. 19. Joseph-Mathurin N, Su Y, Blazey TM, Jasielec M, Vlassenko A, Friedrichsen K, et al. Utility of perfusion PET measures to assess neuronal injury in Alzheimer’s disease. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2018;10:669-77. 20. Ottoy J, Verhaeghe J, Niemantsverdriet E, De Roeck E, Ceyssens S, Van Broeckhoven C, et al. 18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer’s disease: Validation against 15O-H2O PET. Alzheimer’s & Dementia. 2019;15:1172-82. 21. Peretti DE, Vállez García D, Reesink FE, Doorduin J, de Jong BM, De Deyn PP, et al. Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimer’s disease. EJNMMI research. 2019;9:1-9. 22. Peretti DE, Vállez García D, Reesink FE, van der Goot T, De Deyn PP, de Jong BM, et al. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer’s disease PET studies. PloS one. 2019;14:e0211000. 23. Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551-67.

RkJQdWJsaXNoZXIy MjY0ODMw